Clinical Scorecard: Assessment of the Safety and Efficacy of Upadacitinib in Treating Crohn’s Disease Among East Asian Patients: A Post Hoc Evaluation of Phase 3 Randomized Trials

At a Glance

Key Highlights

• Upadacitinib demonstrated efficacy in treating moderately to severely active Crohn's disease.
• The safety profile of upadacitinib was consistent with other indications.
• Responses to conventional therapies in East Asia are often suboptimal, highlighting the need for new treatments.
• Distinct genetic and environmental risk factors for Crohn's disease exist in East Asian populations.
• The prevalence of Crohn's disease is higher among males in East Asia.

Guideline-Based Recommendations

Diagnosis

• Clinical response defined by stool frequency and abdominal pain score.

Management

• Conventional approaches include corticosteroids, aminosalicylates, and immunomodulators.

Monitoring & Follow-up

• Assess clinical and endoscopic outcomes at 12 weeks for induction and 52 weeks for maintenance.

Risks

• Consideration of opportunistic infections such as tuberculosis and hepatitis B in treatment decisions.

Patient & Prescribing Data

Patients aged 18-75 with moderately to severely active Crohn's disease.

Upadacitinib was administered at 45 mg once daily for induction and 15 mg or 30 mg once daily for maintenance.

Clinical Best Practices

• Monitor treatment-emergent adverse events during and after treatment.
• Utilize clinical endpoints such as CDAI and stool frequency for assessing treatment response.

Related Resources & Content

• Clinical Trials
• Clinical Trials
• Clinical Trials